. home.aspx


The More the Merrier: High Doses of Lilly's Trulicity Show Superiority in Reducing Weight and A1C

June 26, 2019 / ALEX KEOWN

Eli Lilly’s type 2 diabetes drug Trulicity hit the mark in a late-stage trial that showed higher doses of the medication significantly reduced A1C from baseline compared to the once-per-week dose of Trulicity currently on the market. Trulicity (dulaglutide) is currently approved for type 2 diabetes in a 1.5 mg dose. The medication is approved to improve blood sugar (glucose) in adults with type 2 diabetes mellitus. Patients in the Phase III AWARD-11 trial received doses of 3.0 mg and 4.5 mg. At 36 weeks, the higher doses showed superiority to the 1.5 mg dose, Indianapolis-based Eli Lilly said this morning.